Product Description | 
GNYTCEVTELSREGKTVIELK, a powerful research-grade tool designed to accelerate discoveries in immunotherapy, cancer biology, and molecular signaling. Derived from the CD47 protein—a critical regulator of immune evasion and cellular homeostasis—this 21-amino-acid peptide is a cornerstone for researchers exploring the intricate interplay between tumor cells and the immune system. Backed by cutting-edge studies, such as those in Molecular Therapy (DOI: S1525-0016(25)00192-3), this peptide offers unmatched specificity and versatility for advancing therapeutic and biological research. Applications in Research The GNYTCEVTELSREGKTVIELK peptide, a segment of the CD47 extracellular domain, is meticulously engineered for a broad spectrum of research applications: - Cancer Immunotherapy: This peptide is instrumental in studying CD47’s role as a “don’t eat me” signal, which tumors exploit to evade phagocytosis by macrophages. It’s ideal for developing anti-CD47 therapies aimed at enhancing immune-mediated tumor clearance.
- Immune Checkpoint Modulation: Investigate how this sequence interacts with signal-regulatory protein alpha (SIRP_) on immune cells, providing insights into blocking CD47-SIRP_ signaling to boost anti-tumor immunity.
- Tumor Microenvironment Studies: Use this peptide to probe the molecular dynamics of cancer cell survival and immune suppression within the tumor microenvironment.
- Drug Development: A key asset for designing peptide-based inhibitors or biologics targeting CD47, supporting precision oncology and novel therapeutic strategies.
- Cell Adhesion and Migration Research: Explore CD47’s influence on integrin-mediated cell adhesion and migration, critical for understanding metastasis and tissue repair.
Functions and Mechanisms The GNYTCEVTELSREGKTVIELK peptide embodies the functional essence of CD47, offering researchers a window into its biological mechanisms: - Phagocytosis Regulation: This sequence is part of the CD47 immunoglobulin-like domain that binds SIRP_, inhibiting phagocytic activity of macrophages and dendritic cells—a mechanism heavily exploited by cancer cells.
- Immune Evasion Inhibition: By mimicking this region, the peptide can be used to disrupt CD47-SIRP_ interactions, promoting immune recognition and destruction of pathological cells.
- High Binding Affinity: The specific arrangement of amino acids—featuring a mix of polar (e.g., Thr, Ser) and charged (e.g., Glu, Lys) residues—ensures strong and selective binding to target proteins, enhancing experimental precision.
- Structural Integrity: Its stable conformation under physiological conditions makes it a reliable candidate for in vitro and in vivo studies.
Biological Importance The GNYTCEVTELSREGKTVIELK peptide is a critical fragment of CD47, a transmembrane protein overexpressed in numerous cancers, including leukemia, lymphoma, and solid tumors like breast and ovarian cancer. Its biological significance includes: - Cancer Progression: CD47’s upregulation on tumor cells correlates with poor prognosis, making this peptide a vital tool for dissecting its role in immune escape and tumor survival.
- Therapeutic Potential: Research, such as that published in Molecular Therapy, highlights CD47-targeted approaches—using peptides like GNYTCEVTELSREGKTVIELK—to sensitize tumors to immune attack, paving the way for combination therapies with checkpoint inhibitors (e.g., anti-PD-1).
- Inflammation and Homeostasis: Beyond oncology, CD47 regulates macrophage activity in inflammatory diseases and red blood cell clearance, making this peptide relevant for studies in autoimmunity and anemia.
- Molecular Insights: The sequence’s involvement in signal transduction pathways offers a deeper understanding of cellular communication, bridging immunology and molecular biology.
Why Choose Our CD47 Peptide (GNYTCEVTELSREGKTVIELK)? - Exceptional Purity: Synthesized at >95% purity using advanced HPLC and mass spectrometry validation for consistent, high-quality results.
- Customizable Options: Available in lyophilized form or solubilized to your specifications, with quantities tailored to your research scale.
- Research-Validated: Aligned with findings from leading journals like Molecular Therapy, ensuring relevance to cutting-edge science.
|
Scientific Background | CD47 Peptide is a 21-residue synthetic peptide with the sequence Gly-Asn-Tyr-Thr-Cys-Glu-Val-Thr-Glu-Leu-Ser-Arg-Glu-Gly-Lys-Thr-Val-Ile-Glu-Leu-Lys. The sequence contains 1 cysteine residue, providing potential thiol/disulfide chemistry when the thiol is available; contains 2 Lys and 1 Arg residues, contributing cationic character. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
